Abstract
aim: To investigate the clinical values of serum tumor markers carcinoembryonic antigen (CEA), glycoprotein antigen (CA) 50, CA19-9, and CA72-4, and the soluble fragment of cytokeratin 19 (CYFRA21-1) in early screening and prognosis prediction of colon cancer.
Methods: 50 patients with colon cancer were enrolled into case group and 50 healthy people undergoing physical examination were enrolled into control group. The expressions of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 in two groups were compared.
Results: It was demonstrated that the expressions of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 among patients in case group were all superior to those among patients in control group (P<0.05), and the expressions of four tumor markers among patients in late group were remarkably superior to those among patients in early group (P<0.05). Postoperative expressions of CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 were notably inferior to preoperative expressions (P<0.05). However, the expressions were apparently higher before treatment when postoperative recurrence and metastasis occurred (P<0.05). The positive detection rates of the combined detection of CA50, CA19-9, CA72-4, and CYFRA21-1 for recurrence and metastasis were all markedly superior to those of single indicator detection (P<0.05).
Conclusion: Tumor markers CEA, CA50, CA19-9, CA72-4, and CYFRA21-1 showed indication significance for detecting positive detection rate, tumor staging, and recurrence and metastasis of colon cancer. The combined detection could improve the detection rate of colon cancer and was conducive to early screening of colon cancer and the determination of prognosis of colon cancer.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.